Recent studies have shown association of the IL23R gene with inflammatory bowel disease, psoriasis and ankylosing spondylitis. We aimed at studying the involvement of IL23R in celiac disease (CD) and multiple sclerosis (MS). We performed a case-control study including 598 patients with CD, 414 with MS and 546 healthy controls, all of them white Spaniards. All samples were genotyped for two single nucleotide polymorphisms: rs7517847 and rs11209026 (Arg381Gln). Statistical analyses were performed using w 2-tests or the Fisher's exact test. The minor allele (Gln) of the coding variant Arg381Gln was significantly increased in CD and MS patients when compared to controls (8% in CD vs 6% in controls, P ¼ 0.02; 9% in MS, P ¼ 0.006). In MS, a stronger effect was observed in patients showing primary-progressive disease (16%, P ¼ 0.004). Moreover, heterozygotes for rs7517847 were significantly increased in this group of MS patients (81% in MS vs 48% in controls, P ¼ 0.0002). In conclusion, contrary to what has been described previously, the less frequent allele of the functional polymorphism Arg381Gln (rs11209026) seems to be increasing susceptibility to CD and MS, although in this last group of patients a stronger effect is observed in patients affected of a primary-progressive form.
Introduction
The discovery in 2000 1 of the new cytokine subunit p19, which together with p40 constitutes interleukin (IL)-23, has forced to reanalyze in last years many of the roles previously attributed to IL-12. Both cytokines, IL-23 and IL-12, are comprised by two subunits: one specific, p19 for IL-23 and p35 for IL-12, and one shared, p40. Since most roles of IL-12 had been addressed based on data regarding the p40 subunit, IL-23 could also be responsible of several functions traditionally attributed to IL-12. In fact, new studies capable of distinguishing between the roles of both cytokines seemed to indicate that IL-23 rather than IL-12 was the key relevant molecule in inflammation. Both cytokines also bind to heterodimeric receptors with unique, IL-23R for IL-23 and IL-12Rb2 for IL-12, and shared, IL-12Rb1, subunits. The discovery of IL-23 has added new complexity to the developmental options open to T cells: the two traditionally considered subsets of T helper (Th) cells, Th1 and Th2, mainly characterized by production of interferon (IFN)-g and IL-4, respectively, must fit with the existence of T cells producing mainly IL-17 in response to IL-23 or IL-1b (human Th17 cells).
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Recent large-scale genetic scans have shown association of several polymorphisms located in the gene coding IL-23R (IL23R) with different inflammatory conditions as Crohn's disease, psoriasis or ankylosing spondylitis. [3] [4] [5] These conditions had been traditionally considered as Th1 diseases and consequently, an important role of IL-12 was expected. However, these new findings seem to indicate a more relevant role of IL-23 on these pathologies. The IL23R coding variant Arg381Gln (rs11209026) was associated with disease, with its minor allele showing protection (381Gln). Although additional variants have been described as associated, probably most of them are not independent (as many of the pairwise r 2 -values between the single nucleotide polymorphisms (SNPs) found to be associated with Crohn's disease 3 are above 0.3).
Multiple sclerosis (MS) and celiac disease (CD) are two inflammatory conditions traditionally considered as typical Th1 diseases, mainly due to the high levels of IFN-g mRNA observed. 6, 7 We aimed at analyzing the involvement of IL23R polymorphisms in these two inflammatory conditions. Additionally, we included in these analyses several polymorphisms of the gene coding for the IL-12p40 subunit (IL12B). Since this pair of molecules is in the same pathway, the disease phenotype can be either the consequence of mutations present simultaneously in both genes or, alternatively, of mutations present in one or the other gene, and in both cases a statistical interaction could be observed.
Materials and methods

Subjects
We studied 598 patients with CD, 414 patients with MS and 546 ethnically matched controls. All samples corresponded to Spanish white individuals and were recruited from the Madrid area (Spain). CD was diagnosed following the European Society for Paediatric Gastroenterology and Nutrition criteria 8 and MS following the Poser criteria. 9 Controls were mainly anonymous blood donors and laboratory staff. A total of 92% of CD patients were HLA-DQ2 positive (DQA1*05 and DQB1*02) and 36% of MS patients were HLA-DRB1*1501 positive. In total 80% of MS patients were affected by the primary progressive (PP) form. Written informed consent was obtained from all subjects. In our control group, 30% of the individuals are HLA-DQ2 positive and 17% positive for HLA-DRB1*1501. This study was approved by the ethics committee of the Hospital Clínico San Carlos (Madrid).
Genotyping
We studied two SNPs on the IL23R gene, on chromosome 1: the intronic polymorphism rs7517847 and the coding variant rs11209026, which codes the amino-acid change Arg381Gln. Moreover, two additional SNPs around the IL12B gene were analyzed: rs6887695 and rs3212227. All SNPs were genotyped by TaqMan technology under conditions recommended by the manufacturer (Applied Biosystems, Foster City, CA, USA).
Statistical analyses
Genotypic, allelic and haplotypic frequency comparisons were performed using the w 2 -test or Fisher's exact test when expected values were below 5. Haplotypic frequencies were estimated using the Expectation-Maximization algorithm implemented in the Arlequin v2.000 software, with number of iterations set at 5000 and initial conditions at 50, with an epsilon value of 10 À7 . Our study has a statistical power above 99% to detect the protection described for rs11209026_A in both group of patients. This power calculation has been performed with EpiInfo v5 considering allelic sample size of controls as 1092 and of patients as 790 (which is the number of MS patients, the smaller patient group), expected frequency in controls as 5.7% and odds ratio (OR) ¼ 0.26 (as described in Duerr et al. ). Interaction was sought by analyzing the distribution of genotypes for one SNP in cases, conditioned by genotypes for the other SNP(s).
Results
All the polymorphisms studied conformed to HardyWeinberg expectations in controls. The analysis of IL23R polymorphisms showed susceptibility to both diseases marked by the presence of rs11209026_A (Gln) ( Table 1 ). The other polymorphism studied, rs7517847, did not show significant differences between patients and controls. Haplotype analysis does not offer additional information: the two haplotypes containing rs11209026_A behave similarly ( Table 2) .
Stratification of patients by the presence of the susceptibility factors HLA-DQ2 or HLA-DRB1*1501 did not show any significant result. However, interesting results emerged when MS patients were subdivided by clinical forms (Table 3) We also studied the possible susceptibility interaction between IL23R and IL12B polymorphisms but no effect was observed (Table 4 ). There are no differences in IL12B genotypes conditioned by IL23R and vice versa. 
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Discussion
We analyzed the role of IL23R polymorphisms in relation to CD and MS and found that the uncommon variant of the functional polymorphism Arg381Gln (rs11209026), coding for glutamine, seems to be increasing susceptibility to both inflammatory conditions. A recent study has reported lack of association of IL23R with CD in the Dutch population 10 and with MS in the US population; 11 this would indicate that population-specific effects may exist, as already suggested by the discordant results regarding MYO9B in CD 12, 13 or tumor necrosis factor (TNF)-376A in MS. 14, 15 In MS, a stronger effect was observed in the group of patients showing PP disease and further analyses are needed to clarify the involvement of Arg381Gln on patients showing RR and SP disease, which constitute the most numerous MS group. It can be argued that spurious results can emerge when very small groups are compared but the highly significant P-value that we obtained makes this possibility unlikely. In both diseases, the Arg381Gln polymorphism seems to be associated with susceptibility independently of IL12B variation.
The relevance of IL23R polymorphisms in autoimmune diseases became first apparent from a genomewide study performed in Crohn's disease, 3 and this result has been repeatedly confirmed [16] [17] [18] [19] [20] [21] [22] including in our population (manuscript submitted). Later, significant association involving this gene was also found with psoriasis and ankylosing spondylitis. 4, 5 In all these studies, the allele 381Gln marks protection. However, most of the studies are being performed in relation to Crohn's disease and it seems increasingly clear that more than one association signal might be present. 23, 24 The presence of two or more mutations involved in disease susceptibility would be in keeping with the results observed in our primary progressive MS patients, which showed a significant increased frequency of heterozygote individuals for the SNP rs7517847 (each allele of this SNP would be in linkage disequilibrium (LD) with a distinct etiologic mutation). The genetic region including IL23R, 1p31.3, shows strong linkage disequilibrium, what makes extremely difficult to attribute the risk/protection observed to any single marker. In fact, as additional SNPs are being included in the subsequent studies, the variants showing the strongest disease association are changing, which suggests that they are not themselves the etiological variants. As a consequence, IL23R SNPs distinct from the two studied might be causing susceptibility in the Spanish population. Notwithstanding, the missense mutation Arg381Gln displayed the strongest association in the original study 3 and association with this polymorphism was replicated in all subsequent studies, including Crohn's disease, psoriasis and ankylosing spondylitis. It is intriguing why the Arg to Gln substitution in codon 381 seems to be causing a different effect in different inflammatory conditions: protection against Crohn's disease, psoriasis and ankylosing spondylitis, and susceptibility to MS and CD. This apparent controversy could be the consequence of different factors. It could be that exactly the opposite molecular effect would be involved in Crohn's disease, and the other pathologies mentioned above, contrasting with CD and MS. Alternatively, the etiologic factor for CD and MS could be different from the etiologic variation causing 25 the prototypical autoimmune mouse model for MS. However, EAE and MS show an important difference regarding IFN-g, the quintessential Th1 cytokine: IFN-g administration leads to suppression of EAE 26 but to exacerbation of MS. 27 In addition, differences between mice and humans regarding the specific role of IL-23 are also emerging as Th17 commitment seems to be driven by IL-23 and/or IL-1b in humans, 2 and by IL-6 and transforming growth factor-b in mice, in which IL-23 acts as a survival/proliferation signal for Th17 committed cells. 28 Our work evidences the involvement of IL23R in CD and MS, especially in the PP form. Further studies are necessary in our or another populations to confirm these results.
